Reminder: FDA's FIRST Authorized AI in Any Field of Medicine Was for Diabetic Retinopathy (IDx-DR / LumineticsCore, April 2018)
Strategic context: vision is the bow wave of clinical AI adoption — not radiology, not pathology, not ambient documentation. The FIRST FDA De Novo authorized autonomous AI in the entire history of US medicine was IDx-DR (now LumineticsCore from Digital Diagnostics) in April 2018, for diabetic retinopathy detection in primary care.
87.2% sensitivity / 90.7% specificity. Two more autonomous AI systems followed: EyeArt (Eyenuk, 2020 — 96% sens / 88% spec for mtmDR), and AEYE-DS (AEYE Health, 2022 — 93% / 91.4%, expanded 2024 for handheld portable).
Plus SCANLY Home OCT (Notal Vision, May 2024) — first FDA-authorized patient-self-operated home OCT. Cahaba Medical Care (AL FQHC) deployment data: AI identified previously-missed DR in >1-in-4 patients screened. CA documented FQHC adopters: Tarzana Treatment Centers (LumineticsCore), San Ysidro Health (EyeArt RCT).
Primary source
FDASource packet
This story's primary source + 4 related tracked stories with theirs — one print-ready digest for your team or board packet.
Free — subscribes you to the weekly Intel Brief. Individual sources are always clickable above, no email needed.
Affected FQHCs
FQHC Talent. (2018, April 11). Reminder: FDA's FIRST Authorized AI in Any Field of Medicine Was for Diabetic Retinopathy (IDx-DR / LumineticsCore, April 2018). Primary source: FDA. Retrieved July 30, 2026, from https://www.fqhctalent.com/intel/fda-first-medical-ai-was-diabetic-retinopathy-2018
More in Strategy & Tactics
Jul 16
Mountain Valleys posts Saturday walk-in access at rural Fall River Valley Health Center
Jul 16
CommuniCare+OLE posts 9 p.m. perinatal and integrated-care hours plus evening dental access at Salud Clinic
Jul 13
TMHP Moves Five More Texas Medicaid Applications to IAMOnline on August 3 — Provider Access Owners Need a Release-3 Cutover Check
Jul 3
TMHP Moves LTC, EVV and Care Forms Applications to IAMOnline With MFA on August 24